Key result
The authors argue that the doses of irbesartan and PD123319 used in their previous study were sufficient to block AT1 and AT2 receptors, disputing claims of insufficient dosing in rats.
No takes yet. Share an insight, caveat, or question.
This letter defends previous findings that AT2 receptor-mediated systemic hemodynamic effects are lacking in anesthetized rats, debating the appropriate dosing of receptor antagonists.
Schuijt et al. (2002) reported a letter. Irbesartan and PD123319 was evaluated. The authors argue that the doses of irbesartan and PD123319 used in their previous study were sufficient to block AT1 and AT2 receptors, disputing claims of insufficient dosing in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: